These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11839572)

  • 1. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.
    Le Poole IC; Riker AI; Quevedo ME; Stennett LS; Wang E; Marincola FM; Kast WM; Robinson JK; Nickoloff BJ
    Am J Pathol; 2002 Feb; 160(2):521-8. PubMed ID: 11839572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
    Ghosh S; Rosenthal R; Zajac P; Weber WP; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
    Ann Surg; 2005 Dec; 242(6):851-7, discussion 858. PubMed ID: 16327495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.
    Klarquist J; Barfuss A; Kandala S; Reust MJ; Braun RK; Hu J; Dilling DF; McKee MD; Boissy RE; Love RB; Nishimura MI; Le Poole IC
    Am J Pathol; 2009 Dec; 175(6):2463-72. PubMed ID: 19893037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes.
    Labarriere N; Pandolfino MC; Raingeard D; Le Guiner S; Diez E; Le Dréan E; Dreno B; Jotereau F
    Int J Cancer; 1998 Oct; 78(2):209-15. PubMed ID: 9754654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.
    Mocellin S; Fetsch P; Abati A; Phan GQ; Wang E; Provenzano M; Stroncek D; Rosenberg SA; Marincola FM
    J Immunother; 2001; 24(6):447-58. PubMed ID: 11759068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
    Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
    J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune selection after antigen-specific immunotherapy of melanoma.
    Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
    Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes.
    Feder-Mengus C; Ghosh S; Weber WP; Wyler S; Zajac P; Terracciano L; Oertli D; Heberer M; Martin I; Spagnoli GC; Reschner A
    Br J Cancer; 2007 Apr; 96(7):1072-82. PubMed ID: 17342088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.
    Pittet MJ; Zippelius A; Speiser DE; Assenmacher M; Guillaume P; Valmori D; Liénard D; Lejeune F; Cerottini JC; Romero P
    J Immunol; 2001 Jun; 166(12):7634-40. PubMed ID: 11390521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1.
    Saleh FH; Crotty KA; Hersey P; Menzies SW
    Int J Cancer; 2001 Nov; 94(4):551-7. PubMed ID: 11745443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
    Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
    J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
    Cormier JN; Hijazi YM; Abati A; Fetsch P; Bettinotti M; Steinberg SM; Rosenberg SA; Marincola FM
    Int J Cancer; 1998 Feb; 75(4):517-24. PubMed ID: 9466650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
    Marincola FM; Hijazi YM; Fetsch P; Salgaller ML; Rivoltini L; Cormier J; Simonis TB; Duray PH; Herlyn M; Kawakami Y; Rosenberg SA
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):192-205. PubMed ID: 8811494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
    Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.